Replimune Group, Inc. $REPL Shares Bought by SummitTX Capital L.P.

SummitTX Capital L.P. grew its holdings in shares of Replimune Group, Inc. (NASDAQ:REPL) by 165.5% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 288,889 shares of the company’s stock after purchasing an additional 180,086 shares during the period. SummitTX Capital L.P. owned about 0.35% of Replimune Group worth $2,210,000 as of its most recent SEC filing.

Other hedge funds have also made changes to their positions in the company. International Assets Investment Management LLC purchased a new position in shares of Replimune Group in the fourth quarter valued at approximately $29,000. Russell Investments Group Ltd. increased its stake in Replimune Group by 3,638.9% during the 3rd quarter. Russell Investments Group Ltd. now owns 7,777 shares of the company’s stock worth $33,000 after buying an additional 7,569 shares during the period. CWM LLC increased its stake in Replimune Group by 248.6% during the 4th quarter. CWM LLC now owns 4,047 shares of the company’s stock worth $39,000 after buying an additional 2,886 shares during the period. BNP Paribas Financial Markets lifted its holdings in Replimune Group by 99.8% during the 3rd quarter. BNP Paribas Financial Markets now owns 13,762 shares of the company’s stock worth $58,000 after buying an additional 6,873 shares in the last quarter. Finally, Raymond James Financial Inc. acquired a new stake in Replimune Group during the 2nd quarter worth approximately $69,000. Institutional investors and hedge funds own 92.53% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms have commented on REPL. Piper Sandler downgraded shares of Replimune Group from an “overweight” rating to a “neutral” rating and set a $4.00 price target for the company. in a research note on Friday, April 10th. BMO Capital Markets upgraded Replimune Group from an “underperform” rating to an “outperform” rating and set a $16.00 price objective on the stock in a research note on Tuesday, June 30th. JPMorgan Chase & Co. upgraded Replimune Group from a “neutral” rating to an “overweight” rating and set a $17.00 target price for the company in a report on Friday, June 26th. Wedbush boosted their target price on Replimune Group from $6.00 to $9.00 and gave the stock a “neutral” rating in a research note on Tuesday, June 30th. Finally, Wall Street Zen upgraded Replimune Group from a “strong sell” rating to a “sell” rating in a report on Saturday, May 23rd. Two investment analysts have rated the stock with a Buy rating, five have assigned a Hold rating and two have given a Sell rating to the company. According to data from MarketBeat.com, Replimune Group currently has a consensus rating of “Hold” and a consensus price target of $8.86.

Insider Activity at Replimune Group

In related news, insider Christopher Sarchi sold 12,000 shares of the stock in a transaction on Monday, June 1st. The stock was sold at an average price of $9.24, for a total value of $110,880.00. Following the transaction, the insider owned 180,962 shares of the company’s stock, valued at $1,672,088.88. This represents a 6.22% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 5.20% of the company’s stock.

Replimune Group Stock Down 38.0%

Shares of Replimune Group stock opened at $5.35 on Wednesday. The company has a quick ratio of 4.79, a current ratio of 4.79 and a debt-to-equity ratio of 0.63. Replimune Group, Inc. has a 52-week low of $1.50 and a 52-week high of $12.50. The company has a market capitalization of $449.08 million, a P/E ratio of -1.58 and a beta of 0.86. The company has a 50 day moving average of $9.35 and a 200 day moving average of $7.39.

Replimune Group (NASDAQ:REPL) last announced its quarterly earnings data on Monday, June 29th. The company reported ($0.76) EPS for the quarter, missing analysts’ consensus estimates of ($0.66) by ($0.10). As a group, research analysts forecast that Replimune Group, Inc. will post -2.44 EPS for the current fiscal year.

About Replimune Group

Replimune Group, Inc is a clinical‐stage biotechnology company focused on developing next‐generation oncolytic immunotherapies for the treatment of solid tumors. The company’s proprietary “RP” platform leverages genetically engineered herpes simplex virus type 1 (HSV-1) vectors armed with immunomodulatory payloads to selectively infect, replicate within and destroy cancer cells, while also stimulating systemic antitumor immune responses.

Replimune’s lead candidate, RP1, incorporates GM-CSF and a fusogenic protein to enhance both direct oncolysis and immune activation.